Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials

Data de publicação: 01/07/2023 Data Ahead of Print: 01/07/2023

Autores da FMUP

[No abstract available]

Neves, J.:: Universidade. Univ Porto, Cardiovasc R&D Ctr UnICRISE, Fac Med, Dept Surg & Physiol, Porto, Portugal

Universidade. Univ Porto, Ctr Hosp Univ Sao Joao, Fac Med, Dept Endocrinol Diabet & Metab, Porto, Portugal

Universidade. Univ Porto, Fac Med, Cardiovasc R&D Ctr UnICRISE, Dept Surg & Physiol, Alameda Hernani Monteiro, P-4200319 Porto, Portugal
Packer, M:: Baylor Univ, Med Ctr, Dallas, TX USA

Imperial Coll, London, England
Ferreira, J.:: Universidade. Univ Porto, Cardiovasc R&D Ctr UnICRISE, Fac Med, Dept Surg & Physiol, Porto, Portugal

Univ Lorraine, CHRU Nancy, F CRIN INI CRCT Cardiovasc & Renal Clin Trialists, Ctr Invest Clin Plurithemat 14 33,Inserm U116, Nancy, France

Universidade. Univ Porto, Fac Med, Cardiovasc R&D Ctr UnICRISE, Dept Surg & Physiol, Alameda Hernani Monteiro, P-4200319 Porto, Portugal

Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Stroke Volume; beta adrenergic receptor blocking agent; cyclic AMP; exendin 4; liraglutide; milrinone; antidiabetic agent; glucagon like peptide 1 receptor; Article; cardiovascular mortality; follow up; heart failure with reduced ejection fraction; heart left ventricle ejection fraction; heart rate; hospitalization; human; meta analysis; prognosis; heart failure; heart stroke volume; hospitalization; non insulin dependent diabetes mellitus